UCB entered a $2.2 billion agreement to acquire Candid Therapeutics, while Celcuity reported positive Phase 3 results for its experimental breast cancer drug gedatolisib in PIK3CA mutant patients. The first ODAC meeting without longtime oncology leader Richard Pazdur spotlighted trial design challenges for AstraZeneca's camizestrant. In regulatory news, the Supreme Court restored mail ordering of mifepristone, reversing a federal appeals court's stay on the abortion pill.
Top Stories
UCB Enters $2.2 Billion Deal to Acquire Candid Therapeutics
Belgian biopharma UCB announced an agreement to acquire Candid Therapeutics for $2.2 billion, as reported by PharmExec. The deal adds to UCB's recent M&A activity and reflects the company's strategy to bolster its immunology portfolio. Worth watching because UCB's acquisition spree suggests aggressive positioning ahead of potential patent cliffs in its core neurology business.
Celcuity's Gedatolisib Succeeds in Phase 3 Breast Cancer Trial
Celcuity announced that two regimens containing its experimental drug gedatolisib met endpoints in PIK3CA mutant patients as part of its Phase 3 trial, building on positive results from last year, Endpoints News reported. The repeat success in this genetically defined patient population strengthens the commercial case for gedatolisib in a crowded breast cancer landscape. This signals potential best-in-class differentiation if the safety profile holds in larger datasets.
Supreme Court Restores Mail-Order Access to Mifepristone
The Supreme Court on Monday restored mail ordering of the abortion pill mifepristone, reversing a federal appeals court's stay that had suspended deliveries, according to Endpoints News and STAT. The decision came after drugmakers requested immediate relief from the lower court ruling. The move suggests the Court is maintaining a fact-based regulatory approach to drug approvals despite political pressure.
First FDA ODAC Meeting Without Pazdur Highlights Conceptual Challenges With AstraZeneca Trial Design
The FDA's first drug-related Oncologic Drugs Advisory Committee meeting in nine months — and the first without longtime oncology leader Richard Pazdur, who left the agency in November 2025 — exposed fundamental questions about novel trial designs, BioSpace reported. The April 30 panel reviewed AstraZeneca's camizestrant, voting 6-3 against approval after questioning whether the SERENA-6 trial's unconventional approach of switching treatment at ESR1 mutation detection — rather than at radiographic progression — could meaningfully demonstrate benefit. Harpreet Singh characterized the design as presenting "conceptual challenges" for evaluating clinical endpoints. The meeting signals that the post-Pazdur FDA oncology division may demand more conventional evidentiary standards, with implications for sponsors pursuing adaptive or biomarker-triggered trial designs.
Windward Bio Raises $165M for Phase 3 Asthma Program
Swiss biotech Windward Bio secured $165 million in financing to advance two experimental medicines derived from China, including a Phase 3 asthma trial, per Endpoints News. The startup combines in-licensed Chinese assets with an in-house discovery team. This signals continued investor appetite for repurposing clinical-stage assets from Chinese biotechs for Western markets despite geopolitical headwinds.
Odyssey Plans $205M IPO Amid Celcuity's Clinical Success
Odyssey Therapeutics announced plans for an initial public offering targeting approximately $225 million, with pricing expected the week of May 4, Fierce Biotech reported. The autoimmune and inflammatory disease-focused biotech, which abandoned a previous IPO attempt last year, plans to list on Nasdaq under the ticker ODTX. Worth watching because the reception will test whether biotech IPO windows remain open for clinical-stage autoimmune platforms.
What to Watch
- Post-Pazdur ODAC standards — The panel's skepticism toward biomarker-triggered switching designs may force sponsors to rethink adaptive trial strategies; watch for whether FDA guidance evolves to address these "conceptual challenges" in future oncology submissions.
- Celcuity regulatory path — Two positive Phase 3 regimens in PIK3CA mutant breast cancer could accelerate NDA timelines; watch for FDA pre-submission meetings.
- Mifepristone precedent — Supreme Court's restoration of mail-order access may influence future litigation around FDA approval authority for controversial therapies.
- Biotech IPO window — Odyssey's $205M IPO will test market appetite for oncology stories; a successful pricing could unlock exits for venture-backed companies.
Market Snapshot
- M&A momentum: UCB's $2.2 billion Candid Therapeutics deal suggests strategic acquirers remain active in immunology despite rising interest rates, with mid-size deals continuing to drive portfolio expansion.
- Targeted oncology validation: Celcuity's PIK3CA-focused success reinforces the commercial viability of genomically stratified breast cancer programs following recent competitor setbacks.
- Oncology regulatory evolution: The post-Pazdur ODAC's skepticism toward unconventional trial designs may raise the evidentiary bar for biomarker-driven approvals, potentially slowing the pace of novel endpoint acceptance in oncology.
